Hemispherx BioPharma, Inc (NYSEMKT:HEB) Presents Influenza Vaccine

860

Dallas, Texas 02/14/2014 (FINANCIALSTRENDS) – In a press release dated Feb 4, 2014, Hemispherx BioPharma, Inc (NYSEMKT:HEB) released a summarized clinical result of its vaccine, which will prevent the pandemic spread of Influenza. The announcement noted that, the summary was the January 30, 2014 presentation the company made at the American Society for Microbiology(ASM) Conference. Additionally, the conference was held under the aegis of the Biodefense Conference which was focused on developing a Universal Vaccine which would prevent the pandemic spread of Influenza.

HEB announces presence of antibodies

HemispherxBioPharma, Inc (NYSEMKT:HEB) at the presentation concluded that the use of its vaccine led to the antibodies detection against High Pathogenic Influenza Strains, in nearly two-thirds of the subjects who were administered the vaccine.

FluMist

HemispherxBioPharma, Inc (NYSEMKT:HEB)  vaccine to fight influenza is the FluMist. This is a vaccine which is used for seasonal influenza and is typically administered through nasal inhalation or intranasally. This is always accompanied by Ampligne which is also a therapy in the experimental phase. The study found that when this vaccine was administered it found that nearly 92% of the subjects were found to have responded with specific antibodies-IgA and it was interestingly, found that atleast one of them was homologus for the vaccine which looked at seasonal vaccines. In those volunteers who did not suffer from any of the influenza conditions too found that the level of IgA antibodies in their body was found to be enhanced.  This was useful in fighting avian influenza virus, which is known to cause pandemic flu in humans. These antibodies found were known to resistant nearly all of the three strains of the bird virus.

The base-line increase in the IgA levels in these patients was found to be, nearly four times more and will also cause increase by over four times the serum HAI as well.

FluMist is now available in European countries as well.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.